key: cord-353963-d3gk3519
authors: Karampela, Irene; Dalamaga, Maria
title: Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
date: 2020-06-06
journal: Arch Med Res
DOI: 10.1016/j.arcmed.2020.06.004
sha: 
doc_id: 353963
cord_uid: d3gk3519

Since the beginning of the COVID-19 pandemic, researchers have focused on repurposing of existing antibiotics, antivirals and anti-inflammatory drugs to find an effective therapy. Fluoroquinolones are broad spectrum synthetic antimicrobial agents, being chemical derivatives of quinoline, the prodrome of chloroquine. Interestingly, fluoroquinolones may exert antiviral actions against vaccinia virus, papovavirus, CMV, VZV, HSV-1, HSV-2, HCV and HIV. A recent in silico study has shown that the fluoroquinolones, ciprofloxacin and moxifloxacin, may inhibit SARS-CoV-2 replication by exhibiting stronger capacity for binding to its main protease than chloroquine and nelfinavir, a protease inhibitor antiretroviral drug. Remarkably, fluoroquinolones have shown multiple immunomodulatory actions leading to an attenuation of the inflammatory response through the inhibition of pro-inflammatory cytokines. Noteworthy, respiratory fluoroquinolones, levofloxacin and moxifloxacin, constitute fist line therapeutic agents for the management of severe community-acquired pneumonia. They are characterized by advantageous pharmacokinetic properties; higher concentrations in the lungs; and an excellent safety profile comparable to other antibiotics used to treat respiratory infections, such as macrolides and b-lactams. Based on their potential antiviral activity and immunomodulatory properties, the favorable pharmacokinetics and safety profile, we propose the use of respiratory fluoroquinolones as adjuncts in the treatment of SARS-CoV-2 associated pneumonia.

since the start of this pandemic, researchers and clinicians have been focused on repurposing of existing antibiotics, antivirals and anti-inflammatory drugs to find an effective therapy to combat COVID-19. However, preliminary clinical trials reported conflicting results regarding the use of the anti-malarial and anti-inflammatory chloroquine and the macrolide azithromycin, while the antiviral remdesivir has not been shown to significantly decrease COVID-19 mortality (1, 2) . Fluoroquinolones are chemical derivatives of quinoline, the prodrome of chloroquine (6) . Indeed, quinoline and quinolone based compounds are being investigated for their antiviral activity against Arch Med Res E20_832 2 various viruses such as Ebola and Dengue virus (7) . Interestingly, fluoroquinolones have also been shown to exert antiviral actions against vaccinia virus, papovavirus, human cytomegalovirus, varicella-zoster virus, herpes simplex virus types 1 and 2, hepatitis C virus and HIV (6, 8, 9) . A recent in silico study demonstrated that the fluoroquinolones, ciprofloxacin and moxifloxacin, exert strong capacity for binding to SARS-CoV-2 main protease (M pro ), indicating that fluoroquinolones may inhibit SARS-CoV-2 replication (10). Furthermore, fluoroquinolones may bind to the M pro active site more strongly than chloroquine and nelfinavir, a protease inhibitor antiretroviral drug used in the treatment of the AIDS. Additionally, experimental studies have demonstrated that levofloxacin exerts anti-oxidative and NO regulatory effects in an animal model of H1N1 influenza virus induced lung injury, and significantly improves survival (11) . In particular, levofloxacin exhibited scavenging actions against neutrophil-derived hydroxyl radicals and suppressed NO production, leading to decreased markers of oxidative stress and NO metabolites in the lungs of H1N1 influenza virus infected animals. Remarkably, fluoroquinolones exhibit multiple immunomodulatory actions leading to attenuation of inflammatory response through the inhibition of pro-inflammatory cytokines such as IL-1 and TNF-α, as shown in experimental and clinical studies (12) . Noteworthy, respiratory fluoroquinolones are characterized by advantageous pharmacokinetic properties, leading to significantly higher concentrations in the lungs compared to serum, as well as an excellent safety profile comparable to other antibiotics used to treat respiratory infections, such as macrolides and blactams (13, 14) .

Considering the potential antiviral activity of respiratory fluoroquinolones against SARS-CoV-2, along with their immunomodulatory properties, their favorable pharmacokinetics and the excellent safety profile, we propose their use as adjuncts in treating patients presenting COVID-19. Therefore, randomized clinical trials of respiratory fluoroquinolones are necessary to explore their potential Arch Med Res E20_832 3 therapeutic effect as an adjunct in the treatment of SARS-CoV-2 associated pneumonia.

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Development of the quinolones

Mode of action of fluoroquinolones

Diagnosis and Treatment of Adults with Communityacquired Pneumonia. An Official Clinical Practice Guideline of the

Antiviral properties of quinolone-based drugs

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus

Fluoroquinolones inhibit HCV by targeting its helicase

Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients

Ciprofloxacin and Moxifloxacin Could Interact with SARS-CoV-2 Protease: Preliminary in Silico Analysis

Pleiotropic Effects of Levofloxacin, Fluoroquinolone Antibiotics, against Influenza Virus-Induced Lung Injury

Immunomodulatory activities of fluoroquinolones

Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state

Moxifloxacin safety: an analysis of 14 years of clinical data

The authors declare that they have no conflict of interest.

None